NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to shrink fatty liver in early trial
Disease control Recruiting nowThis early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug aims to melt liver fat in NASH patients
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Recruiting nowThis early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC